Cipla stock trades at INR 1,311.30, 21.6 percent below its high

Published on 10/12/2026 at 13:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cipla stock was INR 1,311.30 on October 12, 2026, up 0.79 percent. The price was 21.6 percent below the INR 1,673.00 52-week high.

Key points in brief

Cipla stock was last quoted at INR 1,311.30 on October 12, 2026, up 0.79 percent versus INR 1,301.00.
The price was 21.63 percent below the INR 1,673.00 52-week high.
Cipla's market capitalization was INR 1.1 trillion, with a P/E ratio of 31.45 and a 1.00 percent dividend yield.
Cipla is scheduled to report its next quarterly and half-year results on October 27, 2026.

Cipla, INE059A01026, Illustration mit AI erstellt.

Cipla stock was last at INR 1,311.30 on October 12, 2026 at 3:29 p.m. IST, up 0.79 percent from the previous session close of INR 1,301.00. The quote puts the pharmaceutical company 21.63 percent below its 52-week high of INR 1,673.00.

Price remains below yearly high

The 52-week low was INR 1,165.70, leaving the stock INR 145.60 above that floor and INR 361.70 below the high. The one-month change was minus 4.76 percent, while the one-year change was minus 16.70 percent, according to Simply Wall St.

Cipla's market capitalization was INR 1.1 trillion, while its price-to-earnings ratio stood at 31.45 and its trailing dividend yield was 1.00 percent. The valuation figures place the company among India's larger listed pharmaceutical businesses, but the stock's 16.70 percent one-year decline contrasts with its current earnings multiple.

Comparison with peers

Cipla: plus 0.79 percent, P/E 31.45, market capitalization INR 1.1 trillion
Sun Pharmaceutical Industries (NSE, INR): unchanged, P/E 34.91, market capitalization INR 4.2 trillion
Dr. Reddy's Laboratories (NSE, INR): plus 2.71 percent, P/E 30.96, market capitalization INR 1.0 trillion

Next results date is October 27

Cipla is scheduled to report its next quarterly and half-year results on October 27, 2026. The Economic Times reported that the board will consider unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026. That date is the next clearly identified event for the stock.

The latest trailing-twelve-month figures listed by Simply Wall St show revenue of INR 280.68 billion, earnings of INR 33.71 billion and a net profit margin of 12.01 percent, with the earnings period ending June 30, 2026. The figures give the October results a clear numerical benchmark, particularly for profitability.

Trading context stays mixed

Cipla's October 12 quote was higher than the previous session, but the stock remained below its yearly high and below its level from one year earlier. Sun Pharmaceutical Industries was unchanged, while Dr. Reddy's Laboratories gained 2.71 percent, making the peer comparison mixed rather than uniform across Indian pharmaceuticals.